School personnel information

写真b

FUKUSHIMA Kentaro


Gender

Male

Organization 【 display / non-display

  • 2011.04.01 - 2012.09.30, Division of Medicine, Graduate School of Medicine, Assistant Professor

  • 2012.10.01 - 2014.03.31, Division of Medicine, Graduate School of Medicine, Assistant Professor

  • 2017.09.01 - , Division of Medicine, Graduate School of Medicine, Assistant Professor

Education 【 display / non-display

Osaka University Faculty of Medicine  Graduated 1999.03
Osaka University Graduate School, Division of Medical Sciences  Completed 2009.03
 

Academic Papers 【 display / non-display

  • Pre- and post-serial metagenomic analysis of gut microbiota as a prognostic factor in patients undergoing haematopoietic stem cell transplantation., Kusakabe S, Fukushima K, Maeda T, Motooka D, Nakamura S, Fujita J, Yokota T, Shibayama H, Oritani K, Kanakura Y, British journal of haematology, 2019.09, Other

  • Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation., Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, Shibayama H, Tomiyama Y, Kanakura Y., International Journal of Hematology,109(2):197-205, 2019.02, Papers

  • A Novel Unifrac-Based Analytical Method for Determining Sequential Changes in Gut Microbiota after Hematopoietic Stem Cell Transplantation., Shinsuke Kusakabe, Kentaro Fukushima, Tetsuo Maeda, Takafumi Yokota, Ritsuko Nakai, Akihisa Hino, Yasuhiro Nagate, Jiro Fujita, Motooka Daisuke, Shota Nakamura, Hirohiko Shibayama, Yuzuru Kanakura, The American Society of Hematology 60th Annual Meeting,1, 2018.12, Other

  • Addition of melphalan to fludarabine / busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone marrow transplantation/peripheral blood stem cell transplantation., Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, Shibayama H, Tomiyama Y, Kanakura Y, The American Society of Hematology 60th Annual Meeting,1, 2018.12, Other

  • Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation., Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, Shibayama H, Tomiyama Y, Kanakura Y, International journal of hematology, 2018.11, Other

display all >>